Yahoo · Nov 4, 2026
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND-enabling activities for next-generation PI3Kα pan-mutant-selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 BOULDER, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage

